AI Summary
✦ ClarthaPrice Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 19 analysts
Fundamentals
Fundamentals institutional score is 91 using growth durability 90.7.
Valuation
Valuation institutional score is 40 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 64 using mean target upside 15.8%; dispersion penalty 15.9; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 76 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 10 recent ticker-linked news items.
Signal Summary
Market intelligence remains Neutral. fundamentals and technical structure provide support, while valuation remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 18.9% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.65). Confidence: 87%.
Live forward EPS implies next-12-month EPS of ₹15.56. Applying the stock's normalized valuation corridor produces a fair range of ₹666.12 to ₹818.61, with base value near ₹756.68 (+31.8% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹15.56
Forward P/E
36.9x
Base Fair Value
₹756.68
Fair Range
₹666.12 - ₹818.61
Upside To Base
+31.8%
Estimate Source
Live forward EPS
Growth Estimate
+12.7%
5Y Average
47.70
Current
57.82
Overvalued
52.61
Undervalued
42.81
5Y Average
30.16
Current
37.30
Overvalued
34.33
Undervalued
25.19
5Y Average
5.63
Current
6.96
Overvalued
6.41
Undervalued
4.71
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
RAINBOW CHILDRENS MED LTD RAINBOWHospitals & Diagnostic Centres | +33.2% | 15.7% | 53.4x Undervalued | -25% vs avg | +1.2% |
PARK MEDI WORLD LIMITED PARKHOSPSHospitals & Diagnostic Centres | +19.3% | 16.1% | 43.6x Undervalued | -39% vs avg | +95.4% |
THYROCARE TECH LTD THYROCAREHospitals & Diagnostic Centres | +24.3% | 20.1% | 57.1x Undervalued | -20% vs avg | +38.2% |
JUPITER LIFE LINE HOSP L JLHLHospitals & Diagnostic Centres | +18.2% | 12.0% | 54.5x Undervalued | -23% vs avg | +12.9% |
NEPHROCARE HEALTH SERV L NEPHROPLUSHospitals & Diagnostic Centres | +21.2% | 7.7% | 87.3x Premium | +23% vs avg | +48.1% |
NARAYANA HRUDAYALAYA LTD. NHHospitals & Diagnostic Centres | +80.4% | 9.0% | 46.9x Undervalued | -34% vs avg | +6.8% |
GLOBAL HEALTH LIMITED MEDANTAHospitals & Diagnostic Centres | +26.5% | 11.9% | 68.7x Fair | -3% vs avg | +6.9% |
KRISHNA INST OF MED SCI L KIMSHospitals & Diagnostic Centres | +35.3% | 4.8% | 157.6x Premium | +122% vs avg | +10.2% |
METROPOLIS HEALTHCARE LTD trades at a discount (58.1x vs peer avg 71.1x), suggesting potential undervaluation relative to the Hospitals & Diagnostic Centres cohort. Peers include RAINBOW CHILDRENS MED LTD, PARK MEDI WORLD LIMITED, THYROCARE TECH LTD — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹372 CrJun 2026Latest net profit
₹51 CrJun 2026Latest EPS
₹2.44Jun 2026Net margin
25.0%Jun 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Jun 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 256 | 285 | 269 | 292 | 286 | 322 | 297 | 312 | 324 | 356 | 335 | 352 | 372 |
| Expenses + | 198 | 218 | 211 | 218 | 218 | 240 | 232 | 259 | 247 | 264 | 255 | 262 | 279 |
| Operating Profit | 58 | 67 | 59 | 74 | 68 | 82 | 65 | 53 | 77 | 91 | 80 | 90 | 94 |
| OPM % | 23% | 24% | 22% | 25% | 24% | 26% | 22% | 17% | 24% | 26% | 24% | 26% | 25% |
| Other Income + | 3 | 2 | 5 | 2 | 3 | 4 | 3 | 8 | 3 | 3 | -6 | 9 | 5 |
| Interest | 6 | 6 | 5 | 6 | 5 | 5 | 4 | 4 | 4 | 4 | 4 | 7 | 5 |
| Depreciation | 20 | 21 | 24 | 25 | 25 | 26 | 27 | 27 | 28 | 28 | 28 | 33 | 28 |
| Profit before tax | 35 | 42 | 35 | 45 | 42 | 55 | 37 | 29 | 48 | 62 | 42 | 60 | 66 |
| Tax % | 26% | 26% | 23% | 29% | 25% | 23% | 26% | 17% | 25% | 25% | 24% | 27% | 24% |
| Net Profit + | 26 | 31 | 27 | 32 | 31 | 42 | 27 | 24 | 36 | 47 | 32 | 43 | 51 |
| EPS in Rs | 1.28 | 1.53 | 1.30 | 1.55 | 1.53 | 2.06 | 1.34 | 1.15 | 1.72 | 2.25 | 1.55 | 2.09 | 2.44 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome